Clinical Trial Search

Primary: Change in Central Subfield Thickness From Baseline at 12 Months — -50.3 µm — p=<0.001

Primary: Number of Patients With no Disease Activity at Week 16 in the Study Eye — 89 Participants

Primary: The Number of Patients With no Fluid on OCT — 10 participants

Primary: Change From Baseline in BCVA (Best Corrected Visual Acuity) — 5.5; 5.9 Letters correctly read

Primary: Mean Change From Baseline in Visual Acuity — 1.8; 1.0 ETDRS letters

Primary: Number of Responders for Visual Acuity Using Early Treatment Diabetic Retinopathy Study (ETDRS) — 40; 7; 33 participants

Primary: Ocular Safety as Assessed Using Biomicroscopy to Investigate Ocular Tolerability — 0; 0; 1 Participants

Primary: Number of Participant With Improvement in Foveal Thickness (Macular Fluid) as Measured by Optical Coherence Tomography (OCT) — 36 participants

Primary: Change in Macular Drusen Volume — 0.05; 0.11; 20.0; 9.0 mm^3

Primary: Mean Change in Visual Acuity — 15.0; 5.6 letters — p=0.02

Primary: Macular Edema — 416 Microns

Primary: Growth of Geographic Atrophy — 0.18; 0.19 millimeters

Primary: Production of Anti-Retinal Pigment Epithelium (RPE) or Anti-retinal Antibody Formation in Neovascular ("Wet") Age-related Macular Degeneration Patients Compared to…

Primary: Correlation Between Change in Level of Propermeability Factors With Change in Edema After Treatment With a Dexamethasone Implant or Anti-VEGF Agent — 0.47; 0.059; 0.45…

Primary: Visual Acuity (VA) — 8.51; 8.72; 8.67; 8.93 lines of VA

Primary: Visual Acuity - Continuous — -6.1; -1.6; 2.4 Letters seen

Primary: Caliber of Choroidal New Vessel (CNV) — 43.53 micrometer

Primary: Summary of Adverse Events — 57; 16; 47; 4 participants

Primary: Proportion of Subjects With Focal Vitreomacular Adhesion (VMA) Release by Day 28 — 24.3; 12.0 percentage of subjects — p=0.262

Primary: Monthly Rates of Anti-VEGF (Vascular Endothelial Growth Factor) Injections — 0.42; 0.83; 0.34; 0.83 Injections per Month

Primary: The Mean Change at 3 Months in BSCVA From Baseline — 13 letters

Primary: Percentage of Responders Based on CSFT and BCVA Outcomes at Day 14 and Day 28 — 70; 60; 80; 60 percentage of responders

Primary: Highest Tolerated Dose (HTD) of AGN-150998 — 4.2 mg

Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA

Primary: Height (Amplitude) of Multifocal ERG Signal — 2.859 nanovolt/degree^2 — p=<0.05

Primary: Change From Baseline Visual Acuity at 6 Months — 3.8 number of letters

Primary: Change in ETDRS Best Corrected Visual Acuity From Baseline at 54 Weeks — 14 ETDRS letters

Primary: Change From Baseline at Month 1 in Central Subfield Thickness (CSFT) as Measured by Spectral Domain Ocular Coherence Tomography (SD-OCT) — -142.3; -181.6; -175.6; -174.9…

Primary: Number of Subjects Avoiding 15 or More Letter Loss of Best Corrected Visual Acuity From Baseline to 12 Months on an Early Treatment Diabetic Retinopathy Study (ETDRS)…

Primary: BCVA Response Defined as an Increased in 10 Letters at 1 Year Post-implant — 3; 3; 1; 9 eyes